Adam Steensberg, Zealand Pharma CEO

Zealand rides obe­si­ty wave with $1B raise to ad­vance amylin drug and look for a part­ner

Zealand Phar­ma is rais­ing $1 bil­lion to fo­cus on its “crown jew­el” — an amylin ana­log for weight loss — both to ad­vance it in­to a Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.